Company / Working Capital
Actinium Pharmaceuticals, Inc. Working Capital History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$41.4M
FY2025
5-year range
$41.4M / $100.3M
FY2021-FY2025
Trend
-37.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 3 consecutive years, from $100M in FY2022 to $41M in FY2025.
Based on SEC 10-K filings.
$41M in FY2025 with a 3-year CAGR of -25.5%.
Declined from $70M to $41M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -25.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Actinium Pharmaceuticals, Inc.'s working capital has declined for 3 consecutive years.
- 3-year CAGR of -25.5%, indicating a declining trend.
- In FY2025, working capital decreased 37.6% year-over-year.
- Peak working capital was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.4M | -37.6% |
| FY2024 | $66.4M | -4.9% |
| FY2023 | $69.8M | -30.4% |
| FY2022 | $100.3M | +37.6% |
| FY2021 | $72.9M | +7258.8% |
| FY2011 | $990.8K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026